Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Zdravljenje bolnikov s ploščatoceličnim karcinomom glave in vratu z obsevanjem in cetuksimabom
Authors:Strojan, Primož (Author)
Zakotnik, Branko (Author)
Language:Slovenian
Tipology:1.04 - Professional Article
Organisation:Logo OI - Institute of Oncology
Year of publishing:2008
COBISS_ID:701051 Link is opened in a new window
UDC:616-006
ISSN on article:1408-1741
OceCobissID:65324032 Link is opened in a new window
URN:URN:NBN:SI:doc-PMPB2DPT
Note:BSDOCID143366;
Views:1544
Downloads:302
Files:.pdf PDF - Presentation file, download (385,52 KB)
 
Journal:Onkologija
Onkološki inštitut
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:by Authors
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck with Concomitant Irradiation and Cetuximab
Abstract:Contemporary management of locally and regionally advanced squamous cell carcinoma of the head and neck combines simultaneous application of radiotherapy and chemotherapy. With more comprehensive understanding of radiobiological principles of radiotherapy and recent developments in biological drug modeling and technology, more room was provided for improving some other areas of treatment. One of the new promising strategies in the treatment of head and neck carcinomas is the inhibition of epidermal growth factor receptor (EGFR) signaling using anti-EGFR monoclonal antibodies (e.g. cetuximab, Erbitux). In this article, we present the first two patients treated at the Institute of Oncology Ljubljana with the combination of irradiation and cetuximab and discuss theoretical background for the new treatment regime and other possible therapeutic indications for cetuximab in head and neck oncology.

Archive

niGradiv

Back